Phase 2 clinical study for the precise 3DCRT/IMRT technology combined with S-1 in the treatment of elderly patients with locally advanced esophageal squamous cell carcinoma

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900020876

Enrollment

Unknown

Registered

2019-01-21

Start date

2019-02-01

Completion date

Unknown

Last updated

2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophagus squamous cell carcinoma

Interventions

Group1:3DCRT/IMRT technology combined with S-1

Eligibility

Sex/Gender

All

Age

75 Years to 95 Years

Inclusion criteria

Inclusion criteria: 1. Patients volunteered to the research project and signed the Informed Consent; 2. All patients were aged =75 years, both male and female genders were included; 3. Patients with confirmed pathologic diagnoses of ESCC, had not received surgery, radiotherapy, chemotherapy or targeted therapy before this study. 4. According to TNM stages of the 6th AJCC/UICC in esophageal cancer, patients with staging for II to IVA local advanced ESCC were included. 5. No serious hematopoietic function, heart, lung, liver and kidney dysfunction and immunodeficiency. 6. Marrow and hepatorenal functions: leukocytes = 4000/µL, hemoglobin = 90 g/L (without blood transfusion), neutrophil = 2,100/µL and platelet = 100,000/µL, TBil (total bilirubin) < 1.5 times of the upper limit of normal range, AST /ALT=2.5 times of the upper limit of normal range, and creatinine (Cr) =1.5 times of the upper limit of normal range. 7. The loss of weight within 6 months before radiotherapy was less than 10%. 8. The expected survival period was longer than 3 months. 9. Eastern Cooperative Oncology Group (ECOG) score 1-2.

Exclusion criteria

Exclusion criteria: 1. Complete obstruction of the esophagus, deep ulcer or perforation or hematemesis in the esophagus; 2. Participated in other clinical trials at the same time; 3. Interstitial pneumonia or history of interstitial pneumonia; 4. Addicts, such as drug addiction, long-term alcohol abuse, and AIDS patients; 5. Uncontrollable seizures, or lost consciousness of mental illness; 6. History of severe allergies or a specific constitution; 7. Inappropriate to participate in the trial by the judgment of the investigator.

Design outcomes

Primary

Measure	Time frame
tumor size;??? survival rate;??? Local control rate;Progression Free Survival;Toxic reaction;	—

Countries

China

Contacts

Public ContactJinjun Ye

Jiangsu Cancer Hospital

jjye2004@163.com+86 13585175433

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026